Skip to main content

Table 1 Patient demographics and disease characteristics at time of FES PET scan

From: Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Characteristics

N = 56

%

Age, years

 Median

55.5

 

 Range

23–74

 

  < 55 years

25

44.6

  ≥ 55 years

31

55.4

Menopausal status

 Premenopausal a

14

25.0

 Postmenopausal

42

75.0

Disease-free interval b

  > 5 y

31

55.4

  ≤ 5 y

22

39.3

Histology of primary breast cancer

 IDC

49

87.5

 ILC

7

12.5

Hormone-receptor status

 ER-positive and PR-positive

46

82.1

 ER-positive and PR-negative

10

17.9

Metastatic sites

 Nonvisceral

30

53.6

 Bone

37

66.1

  Bone-only

12

21.4

  Visceral disease

26

46.4

  Any lung

13

23.2

  Pleural

7

12.5

  Peritoneum

1

1.8

   Ovarian

2

3.6

   Liver

6

7.0

No. of disease sites

 1

18

32.1

 2

20

35.8

  ≥ 3

18

32.1

De novo metastatic disease

3

5.4

Lines of therapy prior to palbociclib

 0

38

67.9

 1

9

16.1

 2

4

7.1

  ≥ 3

5

8.9

Prior ET for metastatic disease

 None

43

76.8

 Yes

13

23.2

Prior ET type for metastatic disease

 Antiestrogen ± LH-RH analog

8

14.3

 Aromatase inhibitor ± LH-RH analog

9

16.1

Prior chemotherapy for metastatic disease

 None

43

76.8

 Yes

13

23.2

Endocrine therapy following FES PET

 palbociclib + Aromatase inhibitor

19

33.9

 palbociclib + fulvestrant

37

66.1

Outcome

 CR

3

5.4

 PR

6

10.7

 SD

34

60.7

 PD

13

23.2

Clinical benefit

 None

13

23.2

 Yes

43

76.8

PFS

 Events

34

60.7

 Censored

22

39.3

With negative 18F-FES lesions

 None

46

82.1

 Yes

10

17.9

  1. a For premenopausal women, palbociclib combination with endocrine therapy was given upon the administration of gonadotropin-releasing hormone agonist
  2. b Patients with stage IV breast cancer at initial diagnosis were excluded (N = 3)
  3. Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; ET, endocrine therapy; CR, complete responses; PR, partial responses; SD, stable disease; PD, progressive disease; PFS, progression-free survival